Free Trial

Vera Therapeutics (VERA) Stock Price, News & Analysis

Vera Therapeutics logo
$22.29 -0.50 (-2.19%)
Closing price 04:00 PM Eastern
Extended Trading
$22.30 +0.02 (+0.07%)
As of 05:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Vera Therapeutics Stock (NASDAQ:VERA)

Key Stats

Today's Range
$22.09
$23.18
50-Day Range
$18.87
$32.00
52-Week Range
$18.53
$51.61
Volume
663,078 shs
Average Volume
998,885 shs
Market Capitalization
$1.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.00
Consensus Rating
Buy

Company Overview

Vera Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

VERA MarketRank™: 

Vera Therapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 178th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vera Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Vera Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Vera Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.89) to ($3.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vera Therapeutics is -7.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vera Therapeutics is -7.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vera Therapeutics has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Vera Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.23% of the float of Vera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vera Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vera Therapeutics has recently decreased by 98.33%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Vera Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Vera Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.23% of the float of Vera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vera Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vera Therapeutics has recently decreased by 98.33%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Vera Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Vera Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    4 people have searched for VERA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    13 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vera Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,277,598.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    16.30% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vera Therapeutics' insider trading history.
Receive VERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERA Stock News Headlines

Digital Dollar Alert: Protect Your Cash Before It’s Too Late
134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts warn a programmable dollar could erase your privacy and control your spending. A free guide reveals how to protect your savings before the system goes live.
See More Headlines

VERA Stock Analysis - Frequently Asked Questions

Vera Therapeutics' stock was trading at $42.29 at the start of the year. Since then, VERA stock has decreased by 47.3% and is now trading at $22.29.

Vera Therapeutics, Inc. (NASDAQ:VERA) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by $0.06.

Vera Therapeutics (VERA) raised $66 million in an initial public offering on Friday, May 14th 2021. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI acted as the underwriters for the IPO.

Top institutional shareholders of Vera Therapeutics include Platinum Investment Management Ltd. (0.25%), J. Safra Sarasin Holding AG (0.05%), GC Wealth Management RIA LLC (0.02%) and Perigon Wealth Management LLC (0.02%). Insiders that own company stock include Commodore Capital Lp, Patrick G Enright, Sofinnova Venture Partners X,, Carlyle Group Inc, Maha Katabi, Marshall Fordyce, Beth C Seidenberg, Sean Grant, Joseph R Young, Joanne Curley and Celia Lin.
View institutional ownership trends
.

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/08/2025
Today
7/22/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VERA
CIK
1831828
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$100.00
Low Price Target
$26.00
Potential Upside/Downside
+186.3%
Consensus Rating
Buy
Rating Score (0-4)
3.10
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$152.15 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-40.59%
Return on Assets
-34.54%

Debt

Debt-to-Equity Ratio
0.10
Current Ratio
27.68
Quick Ratio
27.68

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.08 per share
Price / Book
2.50

Miscellaneous

Outstanding Shares
63,770,000
Free Float
53,379,000
Market Cap
$1.45 billion
Optionable
Optionable
Beta
1.19

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:VERA) was last updated on 7/22/2025 by MarketBeat.com Staff
From Our Partners